Literature DB >> 17459941

Multiple restrictions of human immunodeficiency virus type 1 in feline cells.

Carsten Münk1, Jörg Zielonka, Hannelore Constabel, Björn-Philipp Kloke, Benjamin Rengstl, Marion Battenberg, Francesca Bonci, Mauro Pistello, Martin Löchelt, Klaus Cichutek.   

Abstract

The productive replication of human immunodeficiency virus type 1 (HIV-1) occurs exclusively in defined cells of human or chimpanzee origin, explaining why heterologous animal models for HIV replication, pathogenesis, vaccination, and therapy are not available. This lack of an animal model for HIV-1 studies prompted us to examine the susceptibility of feline cells in order to evaluate the cat (Felis catus) as an animal model for studying HIV-1. Here, we report that feline cell lines harbor multiple restrictions with respect to HIV-1 replication. The feline CD4 receptor does not permit virus infection. Feline T-cell lines MYA-1 and FeT-1C showed postentry restrictions resulting in low HIV-1 luciferase reporter activity and low expression of viral Gag-Pol proteins when pseudotyped vectors were used. Feline fibroblastic CrFK and KE-R cells, expressing human CD4 and CCR5, were very permissive for viral entry and HIV-long terminal repeat-driven expression but failed to support spreading infection. KE-R cells displayed a profound block with respect to release of HIV-1 particles. In contrast, CrFK cells allowed very efficient particle production; however, the CrFK cell-derived HIV-1 particles had low specific infectivity. We subsequently identified feline apolipoprotein B-editing catalytic polypeptide 3 (feAPOBEC3) proteins as active inhibitors of HIV-1 particle infectivity. CrFK cells express at least three different APOBEC3s: APOBEC3C, APOBEC3H, and APOBEC3CH. While the feAPOBEC3C did not significantly inhibit HIV-1, the feAPOBEC3H and feAPOBEC3CH induced G to A hypermutations of the viral cDNA and reduced the infectivity approximately 10- to approximately 40-fold.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17459941      PMCID: PMC1933292          DOI: 10.1128/JVI.02714-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  85 in total

1.  Host factors regulating post-integration latency of HIV.

Authors:  Samuel A F Williams; Warner C Greene
Journal:  Trends Microbiol       Date:  2005-04       Impact factor: 17.079

2.  A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.

Authors:  P Wei; M E Garber; S M Fang; W H Fischer; K A Jones
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

3.  Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes.

Authors:  Y D Korin; J A Zack
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

4.  Cell cycle arrest in G2/M promotes early steps of infection by human immunodeficiency virus.

Authors:  Bettina Groschel; Frederic Bushman
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Role of the human and murine cyclin T proteins in regulating HIV-1 tat-activation.

Authors:  Y T Kwak; D Ivanov; J Guo; E Nee; R B Gaynor
Journal:  J Mol Biol       Date:  1999-04-23       Impact factor: 5.469

6.  Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses.

Authors:  B J Willett; L Picard; M J Hosie; J D Turner; K Adema; P R Clapham
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

7.  Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice.

Authors:  Z Hanna; D G Kay; N Rebai; A Guimond; S Jothy; P Jolicoeur
Journal:  Cell       Date:  1998-10-16       Impact factor: 41.582

8.  Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat.

Authors:  P D Bieniasz; T A Grdina; H P Bogerd; B R Cullen
Journal:  EMBO J       Date:  1998-12-01       Impact factor: 11.598

9.  The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein.

Authors:  M E Garber; P Wei; V N KewalRamani; T P Mayall; C H Herrmann; A P Rice; D R Littman; K A Jones
Journal:  Genes Dev       Date:  1998-11-15       Impact factor: 11.361

10.  APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication.

Authors:  Qin Yu; Darlene Chen; Renate König; Roberto Mariani; Derya Unutmaz; Nathaniel R Landau
Journal:  J Biol Chem       Date:  2004-10-04       Impact factor: 5.157

View more
  28 in total

1.  Feline Immunodeficiency Virus Vif N-Terminal Residues Selectively Counteract Feline APOBEC3s.

Authors:  Qinyong Gu; Zeli Zhang; Lucía Cano Ortiz; Ana Cláudia Franco; Dieter Häussinger; Carsten Münk
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

2.  Accessory genes confer a high replication rate to virulent feline immunodeficiency virus.

Authors:  Ryan M Troyer; Jesse Thompson; John H Elder; Sue VandeWoude
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

Review 3.  Retroviral restriction and dependency factors in primates and carnivores.

Authors:  Hind J Fadel; Eric M Poeschla
Journal:  Vet Immunol Immunopathol       Date:  2011-06-12       Impact factor: 2.046

4.  FIV diversity: FIV Ple subtype composition may influence disease outcome in African lions.

Authors:  Jennifer L Troyer; Melody E Roelke; Jillian M Jespersen; Natalie Baggett; Valerie Buckley-Beason; Dan MacNulty; Meggan Craft; Craig Packer; Jill Pecon-Slattery; Stephen J O'Brien
Journal:  Vet Immunol Immunopathol       Date:  2011-06-12       Impact factor: 2.046

5.  Vif of feline immunodeficiency virus from domestic cats protects against APOBEC3 restriction factors from many felids.

Authors:  Jörg Zielonka; Daniela Marino; Henning Hofmann; Naoya Yuhki; Martin Löchelt; Carsten Münk
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

6.  High natural permissivity of primary rabbit cells for HIV-1, with a virion infectivity defect in macrophages as the final replication barrier.

Authors:  Hanna-Mari Tervo; Oliver T Keppler
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

7.  Feline immunodeficiency virus envelope glycoproteins antagonize tetherin through a distinctive mechanism that requires virion incorporation.

Authors:  James H Morrison; Rebekah B Guevara; Adriana C Marcano; Dyana T Saenz; Hind J Fadel; Daniel K Rogstad; Eric M Poeschla
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

8.  Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases.

Authors:  Jörg Zielonka; Ignacio G Bravo; Daniela Marino; Elea Conrad; Mario Perković; Marion Battenberg; Klaus Cichutek; Carsten Münk
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

9.  Inhibition of alpharetrovirus replication by a range of human APOBEC3 proteins.

Authors:  Heather L Wiegand; Bryan R Cullen
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

10.  Comparative study on the effect of human BST-2/Tetherin on HIV-1 release in cells of various species.

Authors:  Kei Sato; Seiji P Yamamoto; Naoko Misawa; Takeshi Yoshida; Takayuki Miyazawa; Yoshio Koyanagi
Journal:  Retrovirology       Date:  2009-06-02       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.